FATE (40) IPSC (28) CABA (42) OCGN (35) ⌘ Pro Terminal →

Lineage Cell Therapeutics Inc. (LCTX) — RQD Stock Rating Cockpit

$1.03 -0.96% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.03

Lineage Cell Therapeutics Inc. (LCTX) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $260.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.03 (-0.36%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-12.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LCTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (29/100 Composite)

🔍 WHY LCTX SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (34% of score)

FRED Regime × Technicals: 12% of 52W Range • RSI-14 at 50.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (31% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.99-1% Next Q

Q2 (-2Q)

Grade E$0.98+2% Next Q

Q3 (-1Q)

Grade E$1.00+3% Next Q

Current

Grade E$1.03-9.8% Hist 90D α

Trajectory: E (21) → E (29)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LCTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LCTX currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.02) and Max Pain ($1.08) forces dealer call-delta covering toward $2.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LCTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LCTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 29%NO 71%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

50.830 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE12% OF RANGE

L: $1$1.03H: $2

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 12 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on LCTX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (25)

-35.0% ROIC with 42.0% gross margin and -7.46% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (18)

Altman-Z 0.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (37)

12/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like LCTX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LCTX)

✓Walkthrough of LCTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LCTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -31.79%📐 HORIZONTAL RANGE

2026-10-30O $1.04H $1.05L $0.98C $1.03VOL 1.17M

RES: $1.41SUP: $0.76SMA50: $1.02SMA200: $1.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LCTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LCTX Butterfly Map → + Track LCTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +53.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LCTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LCTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LCTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LCTX)

Health Care Rank #954 of 1016 ⚔️ FATE vs LCTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LCTX vs. FATE, IPSC, CABA, OCGN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lineage Cell Therapeutics Inc. (LCTX) ranks #954 by composite RQD confidence (29/100, grade E) and #541 by equity capitalization ($260.5M). Within this direct 5-issuer industry benchmark cohort, LCTX leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. CABA currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with LCTX at 29/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LCTX ACTIVE Lineage Cell Therapeutics Inc.	E	29/100	—	—	-35.0%	-0.96%	$260.5M	Benchmark Subject
FATE Fate Therapeutics Inc.	D-	40/100	—	—	-35.0%	0.00%	$260.0M	/fate-vs-lctx →
IPSC Century Therapeutics Inc.	E	28/100	—	—	-14.1%	-2.67%	$264.4M	/ipsc-vs-lctx →
CABA Cabaletta Bio Inc.	D-	42/100	—	—	-35.0%	+4.28%	$268.7M	/caba-vs-lctx →
OCGN Ocugen Inc.	D-	35/100	—	—	-35.0%	-4.15%	$252.4M	/ocgn-vs-lctx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000876343

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lineage Cell Therapeutics Inc. (LCTX) reported GAAP revenue of $14.6M (+53.2% vs. FY2024 revenue of $9.5M , and +62.7% cumulative change since FY2023) , GAAP net income of -$63.5M, operating cash flow of -$18.9M, and free cash flow of -$19.4M (+17.8% YoY). On the balance sheet, LCTX closed FY2025 with $112.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$14.6M	-$63.5M	-$18.9M	-$19.4M	$112.6M	—
FY2024 (FY)	2024-12-31	$9.5M	-$18.6M	-$23.1M	-$23.7M	$113.2M	—
FY2023 (FY)	2023-12-31	$8.9M	-$21.5M	-$28.6M	-$28.6M	—	—

3. LCTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lineage Cell Therapeutics Inc. (NYSE: LCTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.03 (-0.96% 1D, market cap $260.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LCTX ranks #954 in composite RQD confidence.

How does LCTX compare to FATE and IPSC in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LCTX carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FATE (Fate Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $260.0M) and IPSC (Century Therapeutics Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -14.1%, cap $264.4M). Among the 5-stock peer group, LCTX leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LCTX?

Per LCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000876343), Lineage Cell Therapeutics Inc. generated $14.6M in revenue (+53.2% YoY), -$63.5M in net income, and -$19.4M in free cash flow against $112.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LCTX trading relative to its 50-day, 200-day, and 52-week technical levels?

LCTX last traded at $1.03 (-0.96% on volume of 937,738 shares), positioning the stock +0.98% above its 50-day simple moving average ($1.02) and -22.56% below its 200-day simple moving average ($1.33). Across its 52-week range of $0.88 to $2.09, LCTX sits at the 12.4% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.16).

LCTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell LCTX stock right now?

Lineage Cell Therapeutics Inc. (LCTX) currently earns a Roarable Rating of E (Strong Sell — SELL) with 29/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is LCTX's 12-month price target and RQD AI Jury consensus?

LCTX's 12-month base price target is $0.9 (range $0.7 to $2.19), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: LCTX RQD Cockpit LCTX 12M Forecast LCTX Earnings & Move LCTX Dividends & DRIP LCTX Insiders & 13F LCTX Whale Options LCTX Profit Sankey LCTX News & Why